IBP Ventures helps improve cryopreservation performance in IVF, cell therapy, biologics and research preservation using engineered ice-binding proteins, assessed through focused commercial feasibility pilots.
We work with clinics, therapy developers, and preservation teams to evaluate whether targeted ice-interface control can improve performance in defined freeze–thaw workflows.
In cryopreservation, post-thaw performance is frequently constrained by ice crystal damage and recrystallisation during freezing, storage, and thawing.
Even where protocols are well developed, freeze-related stress can still reduce viability, affect recovery, and introduce avoidable losses into high-value biological workflows including IVF, cell therapy, biologics and biobanking.
This often translates directly into yield loss, variability, and higher cost per viable unit.
Instead of relying solely on bulk cryoprotectant optimisation, we aim to influence ice behaviour more directly.
Our work focuses on engineered ice-binding proteins that interact with the ice surface, with the goal of suppressing recrystallisation and improving the preservation environment for sensitive biological material.
We offer tightly scoped feasibility pilots for organisations that want to evaluate whether ice-binding proteins can improve performance in a defined freeze–thaw workflow.
Each pilot is structured to generate practical data under relevant conditions, without requiring a large upfront commitment or long-term platform lock-in.
Define the exact failure point in your workflow, the biological material, and the performance measures that matter.
Cryo-Dock modelling is used to support candidate prioritisation before laboratory work begins.
Selected candidates are tested in the context of your biological system and relevant freeze–thaw conditions.
Indicative range depending on system complexity, assay requirements, and testing scope.
Typical decision point: continue development, optimise formulation, or discontinue early.
We prioritise workflows where preservation quality, post-thaw viability, and freeze-related losses have direct clinical or commercial consequences.
Evaluate whether targeted control of ice behaviour can support improved embryo survival, oocyte survival and post-thaw viability through demanding IVF cryopreservation workflows.
Assess potential improvements in preservation performance for sensitive cells, formulations, or advanced therapeutic products exposed to freezing and cold-chain stress.
Explore whether engineered ice-interface control can enhance long-term storage quality for critical research, diagnostic, or commercial biological samples.
We are most relevant where freeze–thaw performance is already recognised as a real constraint on quality, recovery, consistency, or cost. Selected secondary applications in industrial icing may also be considered where there is clear technical fit.
IBP Ventures supports organisations working in cryopreservation across IVF, cell therapy, biologics and research preservation. Our feasibility pilots assess whether ice-binding proteins can reduce freeze damage, improve post-thaw survival, and improve recovery in demanding freeze–thaw workflows.
Improve embryo survival, oocyte survival and post-thaw performance in IVF workflows.
IVF →Support recovery, viability and preservation quality for sensitive therapeutic cells.
Cell therapy →Reduce preservation loss and strengthen long-term sample quality during storage and thaw.
Biobanking →A practical first step to assess technical fit before larger development commitments.
Feasibility Pilot →We use computational pre-screening to help reduce experimental risk before wet-lab work begins.
Cryo-Dock supports the design and assessment of candidate ice-binding proteins by modelling likely protein–ice interaction behaviour under relevant conditions.
Cryo-Dock is not a general protein modelling tool — it is designed specifically to evaluate protein–ice interactions.
This pre-screening approach is intended to improve candidate selection, shorten development cycles, and increase confidence before pilot-stage testing.
The work is focused on applied performance in defined client systems, with decisions driven by practical outcomes rather than publication outputs.
IBP Ventures is focused specifically on the interaction between ice-binding proteins and freezing behaviour, rather than offering broad generic discovery or biofoundry services.
Candidate design logic, protein production experience, and application assessment are brought together in one practical commercial pathway.
The business is structured around a clear entry point: solve a defined preservation problem in a real workflow, then expand from evidence rather than overclaiming platform reach too early.
Founder-led development informed by practical bioprocess and scale-up experience, including fermentation capability developed through work with CRO.
Many technically interesting biotech propositions struggle because they begin with a broad platform claim and no practical entry point.
IBP Ventures is positioned differently: start with a defined commercial problem, offer a contained validation route, and build from real client evidence.
At this stage, the primary commercial entry point is a defined feasibility pilot. The objective is to determine whether engineered ice-binding proteins can improve performance in a specific client workflow before any larger development commitment is made.
The focus is on influencing ice behaviour more directly at the interface, rather than relying only on bulk formulation changes. That does not replace broader cryopreservation optimisation, but it may offer a more targeted mechanism in suitable systems.
No. Cryo-Dock is positioned as a specialist computational engine for evaluating likely protein–ice interactions and supporting candidate pre-screening. Its value is in reducing development uncertainty within this specific technical domain.
The best early fit is an organisation already experiencing meaningful freeze–thaw constraints in a valuable workflow, and where improved preservation performance would have a clear technical, clinical, or commercial payoff.
Tell us where viability loss, recovery issues, or freeze-related instability occur in your process.
We will provide an honest view on whether a feasibility pilot is likely to be a sensible next step.
We typically work with organisations actively running or developing freeze–thaw workflows.